
Dynavax Technologies (DVAX) Stock Forecast & Price Target
Dynavax Technologies (DVAX) Analyst Ratings
Bulls say
Dynavax Technologies Corp is demonstrating promising progress in its vaccine candidates, with reported vaccine response rates for the selected 100ug dose being comparable to those of Shingrix, alongside notably improved tolerability. The company has received encouraging results regarding tolerability and CD4+ T-cell responses for its Z-1018 shingles vaccine candidate, aligning with management's immunogenicity and tolerability goals. This positive momentum, along with the substantial revenue generation from its existing products CpG 1018 and HEPLISAV-B, underscores a favorable outlook for Dynavax's financial performance.
Bears say
Dynavax Technologies Corp faces significant challenges in advancing its clinical candidates, as future products may fail to meet efficacy and safety standards necessary for approval and commercialization. The company also contends with potential difficulties in effective commercialization due to market conditions, strong competition, and internal factors that could hinder growth. Additionally, Dynavax may struggle to secure acceptable partnership terms for its candidates, further jeopardizing the success of its commercial launches.
This aggregate rating is based on analysts' research of Dynavax Technologies and is not a guaranteed prediction by Public.com or investment advice.
Dynavax Technologies (DVAX) Analyst Forecast & Price Prediction
Start investing in Dynavax Technologies (DVAX)
Order type
Buy in
Order amount
Est. shares
0 shares